



IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 12 Issue: II Month of publication: February 2024 DOI: https://doi.org/10.22214/ijraset.2024.58345

www.ijraset.com

Call: 🕥 08813907089 🔰 E-mail ID: ijraset@gmail.com



Artificial Intelligence in Antibiotic Discovery Against Superbugs

Djosci Coêlho de Sá Júnior

Medical student at the University of Gurupi (UnirG), 1585 Rio de Janeiro Av, Gurupi, Brazil

Abstract: This article explores the pivotal role of artificial intelligence (AI) in combating antibiotic-resistant bacteria, emphasizing its potential to accelerate antibiotic discovery and improve treatment outcomes. It highlights recent advancements in AI-driven research that demonstrate the feasibility of identifying novel antibiotic candidates and the challenges faced, such as data quality and algorithm development. The integration of AI in this field is seen as a promising solution to the global health threat posed by drug-resistant pathogens, offering new strategies for developing effective antibiotics. The review also underscores the necessity for interdisciplinary collaboration and further research to enhance AI's predictive accuracy and application in drug development processes.

Keywords: Artificial Intelligence (AI); Antibiotic-resistant bacteria; Antibiotic discovery; Drug-resistant pathogens; Drug development processes

I. INTRODUCTION

The rise of antibiotic-resistant bacteria, commonly referred to as "superbugs," poses a significant threat to global health, necessitating innovative strategies for antibiotic discovery. The integration of artificial intelligence (AI) into this search represents a pivotal shift in the battle against superbugs, offering the potential to accelerate the identification of novel antibiotic candidates and predict their efficacy. However, the practical application of AI-driven antibiotic discovery faces challenges such as the need for high-quality, interoperable datasets and the development of accurate prediction algorithms. Despite these hurdles, recent advances have demonstrated the feasibility and value of AI in identifying new antibiotics, serving as a catalyst for further research and investment in AI-enabled drug discovery (Melo et al., 2021).

The continuous increase of drug-resistant pathogens is a significant challenge for the treatment of infectious diseases (Zheng et al., 2017). This underscores the urgency for innovative approaches such as AI-driven antibiotic discovery to combat antimicrobial resistance. AI technologies have the potential to integrate and analyze data from different sources, offering a promising solution to the challenges posed by low diagnostic rates and the geographical dispersion of rare diseases (Brasil et al., 2019).

The application of AI in combating high antimicrobial resistance rates has been recognized as essential by organizations such as the World Health Organization (WHO) (Rabaan et al., 2022). The use of AI for antimicrobial resistance prediction can provide clinicians with useful information regarding possible antibiotic resistance, aiding in the selection of appropriate empirical antibiotic therapy (Feretzakis et al., 2021).

Recent advances in AI methodologies applied to the fight against superbugs have demonstrated the potential of AI in accelerating the discovery of new antibiotics and overcoming the challenges posed by antimicrobial resistance. These advancements offer hope in addressing one of the most pressing health challenges of our time.

II. METHODS

This literature review employs a comprehensive and systematic approach to synthesize recent advances in artificial intelligence (AI) as applied to the discovery of antibiotics effective against antibiotic-resistant bacteria, or superbugs. Given the interdisciplinary nature of this field, encompassing computer science, microbiology, pharmacology, and bioinformatics, our methodology is designed to capture a broad spectrum of relevant research, spanning theoretical foundations, algorithmic developments, and practical applications.

Initially, we defined a set of criteria for inclusion that focused on publications from the past seven years, prioritizing peer-reviewed articles, reviews, and significant case studies that directly address the use of AI in antibiotic discovery. This time frame was selected to ensure the review's relevance to current technologies and methodologies. Databases such as PubMed, Web of Science, and Google Scholar served as primary sources for literature search, supplemented by references from relevant articles and reports from major conferences and symposia in the fields of AI and drug discovery.



Volume 12 Issue II Feb 2024- Available at www.ijraset.com

The search strategy was structured around a combination of keywords and phrases related to "artificial intelligence," "machine learning," "deep learning," "antibiotic discovery," "antimicrobial resistance," and "drug development." Boolean operators (AND, OR) were utilized to refine the search and capture a comprehensive dataset of publications. This was followed by a manual screening process to filter out articles that did not meet the inclusion criteria, ensuring that only studies with significant contributions to the field were considered.

Data extraction from the selected studies involved summarizing key findings, methodologies, AI techniques used, targets explored, and the nature of antibiotic compounds identified. This process was critical for identifying trends, common challenges, and gaps in the current research landscape. Special attention was given to studies that reported novel AI approaches, demonstrated successful identification of antibiotic candidates, or provided insights into the mechanisms of action and resistance.

To ensure a balanced and critical analysis, the review also considered the limitations and challenges reported in the studies, including issues related to data quality, algorithmic biases, scalability of methods, and translational hurdles from computational models to clinical application. This comprehensive examination allows for a nuanced understanding of where AI stands today in the quest for new antibiotics and what hurdles must be overcome to realize its full potential.

Finally, the synthesis of collected data aimed to highlight innovative AI strategies, key successes in identifying novel antibiotics, and the implications of these advancements for future research directions. By juxtaposing recent achievements against ongoing challenges, the review seeks to provide a clear and informed perspective on the role of AI in overcoming the global threat posed by superbugs, paving the way for a new frontier in antibiotic discovery.

III. DISCUSSION

The integration of artificial intelligence (AI) in antibiotic discovery has led to significant breakthroughs, demonstrating promising potential in addressing the challenge of multidrug-resistant bacterial infections. The innovative application of AI algorithms has facilitated the identification of a novel antibiotic, abaucin, which demonstrated targeted efficacy against Acinetobacter baumannii, a formidable superbug. This specificity is particularly beneficial for maintaining the balance of beneficial microbiota and mitigating the risk of developing antibiotic resistance (David et al., 2021). Furthermore, the employment of explainable AI has led to the identification of a new class of antibiotic candidates, demonstrating AI's capacity not only in predicting antibacterial properties but also in elucidating the chemical foundations of these properties. The acceleration of the drug discovery process through AI is noteworthy, as AI algorithms have the capability to sift through extensive chemical libraries, identifying potential antibiotics in a fraction of the time taken by conventional methods (Melo et al., 2021). Additionally, the contributions detailed herein not only augment our comprehension of AI's capacity to streamline and refine the drug discovery process but also forge a path towards the development of novel antibiotics, addressing the critical global health challenge posed by antibiotic-resistant bacteria (David et al., 2021). The use of AI in antibiotic discovery has markedly broadened the extent of compound screening, enabling the assessment of millions of molecules and leading to the discovery of promising antibiotic candidates (Rahman et al., 2022). This exemplifies the transformative role of AI in the field of antibiotic discovery, leveraging machine learning models to identify compounds with innovative mechanisms of action and specificity for targeted pathogens. The progression from initial discovery towards clinical application encompasses the optimization of the chemical structures of identified compounds, alongside rigorous preclinical and clinical evaluations, highlighting the potential for developing effective treatments for infections resistant to existing antibiotics (David et al., 2021).

The integration of artificial intelligence (AI) into antibiotic discovery has marked a significant advancement in the field, offering the potential to address the critical need for innovative antibiotics to combat drug-resistant pathogens. AI has demonstrated the ability to rapidly parse through extensive chemical libraries, identify compounds with unique antibacterial properties, and delineate their mechanisms of action, exemplified in the targeting of *Acinetobacter baumannii* and Methicillin-resistant *Staphylococcus aureus* (MRSA). This strategic application of AI has led to the pinpointing of compounds with significant efficacy against challenging pathogens, paving the way for the development of targeted treatment strategies that could bypass current resistance mechanisms. Furthermore, AI has the potential to enhance and expedite the antibiotic discovery process, potentially diminishing the time and financial investments required to bring new antibiotics to the market (Melo et al., 2021).

However, the efficacy of AI and machine learning models is contingent upon the availability of extensive, high-quality datasets for training, which may pose a challenge. Additionally, despite AI's ability to predict a compound's antibacterial potential, empirical validation through laboratory and animal studies remains a crucial step in confirming these predictive insights. Moreover, the journey from discovery to clinical implementation is complex and laden with hurdles, including the need for regulatory approvals and the demonstration of safety and efficacy in human populations (Melo et al., 2021).



International Journal for Research in Applied Science & Engineering Technology (IJRASET)

ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538 Volume 12 Issue II Feb 2024- Available at www.ijraset.com

IV. CONCLUSION

Future research should aim to refine AI algorithms to improve their predictive precision and transparency, broaden the scope of bacterial targets, and extend the application of AI across different phases of drug development, such as optimization and toxicity testing, to further enhance its utility. Integration of AI with novel biotechnological methods may reveal untapped opportunities for antibiotic discovery, emphasizing the need for interdisciplinary collaboration among computer scientists, microbiologists, and clinical researchers to leverage this potential and propel the development of next-generation antibiotics forward (Melo et al., 2021). In conclusion, while the integration of AI into antibiotic discovery holds immense promise in combating the threat posed by drug-resistant pathogens, it is essential to address the challenges and limitations associated with its application to realize its full potential in medical settings.

REFERENCES

- [1] Melo, M., Maasch, J., & Fuente-Núñez, C. (2021). Accelerating antibiotic discovery through artificial intelligence. Communications Biology, 4(1). https://doi.org/10.1038/s42003-021-02586-0
- Zheng, W., Sun, W., & Simeonov, A. (2017). Drug repurposing screens and synergistic drug-combinations for infectious diseases. British Journal of Pharmacology, 175(2), 181-191. <u>https://doi.org/10.1111/bph.13895</u>
- [3] Brasil, S., Pascoal, C., Francisco, R., Ferreira, V., Videira, P., & Valadão, G. (2019). Artificial intelligence (ai) in rare diseases: is the future brighter?. Genes, 10(12), 978. <u>https://doi.org/10.3390/genes10120978</u>
- [4] Rabaan, A., Alhumaid, S., Mutair, A., Garout, M., Abulhamayel, Y., Halwani, M., ... & Ahmed, N. (2022). Application of artificial intelligence in combating high antimicrobial resistance rates. Antibiotics, 11(6), 784. <u>https://doi.org/10.3390/antibiotics11060784</u>
- [5] Feretzakis, G., Sakagianni, A., Loupelis, E., Kalles, D., Skarmoutsou, N., Martsoukou, M., ... & Dimitrellos, E. (2021). Machine learning for antibiotic resistance prediction: a prototype using off-the-shelf techniques and entry-level data to guide empiric antimicrobial therapy. Healthcare Informatics Research, 27(3), 214-221. <u>https://doi.org/10.4258/hir.2021.27.3.214</u>
- [6] David, L., Brata, A., Mogosan, C., Preda, C., Czako, Z., Muresan, L., ... & Popa, S. (2021). Artificial intelligence and antibiotic discovery. Antibiotics, 10(11), 1376. <u>https://doi.org/10.3390/antibiotics10111376</u>
- [7] Rahman, A., Liu, C., Sturm, H., Hogan, A., Davis, R., Hu, P., ... & Cardona, S. (2022). A machine learning model trained on a high-throughput antibacterial screen increases the hit rate of drug discovery. Plos Computational Biology, 18(10), e1010613. <u>https://doi.org/10.1371/journal.pcbi.1010613</u>











45.98



IMPACT FACTOR: 7.129







INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089 🕓 (24*7 Support on Whatsapp)